Transitioning to Alternative Approaches

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line chemotherapy options alongside novel strategies such as targeted agents, antibody-drug conjugates, and clinical trial enrollment. The discussion will address toxicity considerations and goals of care in the post-progression setting. Examine strategies for transitioning to alternative approaches beyond standard cytotoxic therapy in patients with progressive lung cancer. Speakers will review emerging treatment options, including targeted therapies, antibody-drug conjugates, novel immunotherapy strategies, and clinical trial opportunities. The discussion will address biomarker-driven decision-making, safety considerations, and patient selection, giving participants insight into how innovative therapeutic approaches may improve outcomes after chemoimmunotherapy failure.